Novynette (Desogestrel, Ethinylestradiol)

Desogestrel acts as a progestogen that suppresses the luteinising hormone surge, while ethinylestradiol provides estrogenic feedback that stabilises the endometrium and reinforces negative feedback on gonadotropins. Together they inhibit ovulation, thicken cervical mucus, and alter the uterine lining, creating multiple barriers to fertilisation and implantation.

The dosing regimen for Novynette is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions should follow the prescriber’s guidance.

Novynette is contraindicated in known or suspected pregnancy and should not be started during pregnancy. It is generally not recommended for breastfeeding women because hormonal contraceptives can affect milk production; a healthcare provider should evaluate alternative options.

To order Novynette, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Novynette contains desogestrel, a third‑generation progestogen, which may offer a lower incidence of androgenic side effects such as acne compared with older progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, but individual tolerability and risk profiles can differ.

Novynette tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Novynette is taken orally as a tablet. The usual regimen is one tablet each day, preferably at the same time, for 21 consecutive days followed by a hormone‑free interval (typically 7 days) during which withdrawal bleeding occurs.

The most serious risks include venous or arterial thromboembolism (blood clots), stroke, myocardial infarction, and severe hypertension. Patients with a history of clotting disorders, smoking, or certain cardiovascular conditions should be evaluated carefully before starting therapy.

Novynette should not be used by women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or are smokers aged 35 years or older. Contraindications are detailed in the product’s prescribing information.